VVOS News and Press, Vivos Therapeutics Inc. From 11/22/22

Detailed Analysis Finds Minimal Impact on Prior Financial Results; No Previously Reported Revenue to be Lost Previously Reported First Quarter 2022 Revenue Expected to Increase Approximately $200,000; No Need to Restate Prior Year Financial Statements Restated ...

Vivos Therapeutics ( NASDAQ: VVOS ) receives a non compliance notice from Nasdaq over delay in timely filing of its quarterly report on Form 10-Q for the quarter ended June 30, 2022. The delay in filing is a result of ongoing company analysis and related discussions betwee...

LITTLETON, Colo., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos” or the “Company”) today announced that it has received a notice (“Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (&#...

For the second time, Vivos Therapeutics has delayed the release of its Q2 2022 financial results . The release was first expected on August 15. However, on that date, the company said results would be delayed due to "ongoing Company analysis and related discussions between...

Vivos Therapeutics (NASDAQ: VVOS) , a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, has reported a delay in releasing its Q2 2022 finan...

LITTLETON, Colo., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS) (“Vivos”) is providing an update on the delay in announcing its second quarter 2022 financial results. “We are disappointed it is taking longer than usual to report our fin...

Vivos Therapeutics (NASDAQ: VVOS) , a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, has announced that it will be rescheduling the rele...

LITTLETON, Colo., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to mod...

Vivos Therapeutics (NASDAQ: VVOS) , a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, will release its second quarter 2022 financial resu...

LITTLETON, Colo., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to mod...